Filter Results
:
(627)
Show Results For
-
All HBS Web
(627)
- People (2)
- News (55)
- Research (438)
- Events (2)
- Multimedia (5)
- Faculty Publications (390)
Show Results For
-
All HBS Web
(627)
- People (2)
- News (55)
- Research (438)
- Events (2)
- Multimedia (5)
- Faculty Publications (390)
- November 1991
- Case
Monsanto's March into Biotechnology (B) (Abridged)
By: Dorothy Leonard-Barton and Alistair D. Williamson
Keywords:
Biotechnology Industry
Leonard-Barton, Dorothy, and Alistair D. Williamson. "Monsanto's March into Biotechnology (B) (Abridged)." Harvard Business School Case 692-067, November 1991.
- February 1992
- Case
U.S. Biotechnology Industry in 1987 (Abridged)
By: Dorothy Leonard-Barton and Alistair D. Williamson
Leonard-Barton, Dorothy, and Alistair D. Williamson. "U.S. Biotechnology Industry in 1987 (Abridged)." Harvard Business School Case 792-077, February 1992.
- 31 May 2024
MS/MBA Biotechnology Life Sciences Information Session
Join us for a virtual event with program faculty and Admissions staff to learn more about Harvard's MS/MBA Biotechnology: Life Sciences joint degree.
View Details
- 09 Jul 2019
- Blog Post
Solving the Complexities of the Biotechnology Industry
Biotechnology is a complex industry which combines applied science & engineering and applied business practices with life science. It is the most multi-faceted industry segment there is because it is ultimately focused on the most...
View Details
- March 1992 (Revised June 2005)
- Teaching Note
Monsanto's March into Biotechnology (A), Teaching Note
By: Dorothy Leonard-Barton and Alistair D. Williamson
Teaching Note for (9-690-009).
View Details
Keywords:
Biotechnology Industry
- 1988
- Chapter
Joint Ventures and Collaboration in the Biotechnology Industry
By: Gary P. Pisano, W. Shan and David Teece
- January 2000
- Article
The Tragedy of the Commoners: Biotechnology and its Publics
By: Arthur A. Daemmrich
Keywords:
Biotechnology Industry
Daemmrich, Arthur A. "The Tragedy of the Commoners: Biotechnology and its Publics." Nature Biotechnology 18, no. 1 (January 2000): 2–4.
- March 2011
- Case
MorphoSys AG: The Evolution of a Biotechnology Business Model
By: Gary P. Pisano, Ryan Johnson and Carin-Isabel Knoop
In the biotech world, the 18-year-old Munich-based company MorphoSys was a rarity: it was profitable. The company achieved this profitability not by developing and selling its own drugs, but by licensing access to its proprietary library of human antibodies. Recently,...
View Details
Keywords:
Business Model;
Profit;
Intellectual Property;
Rights;
Risk Management;
Digital Platforms;
Product Development;
Business and Shareholder Relations;
Vertical Integration;
Biotechnology Industry;
Munich
Pisano, Gary P., Ryan Johnson, and Carin-Isabel Knoop. "MorphoSys AG: The Evolution of a Biotechnology Business Model." Harvard Business School Case 611-046, March 2011.
- Article
Do Equity Financing Cycles Matter?: Evidence from Biotechnology Alliances
By: Josh Lerner, Hilary Shane and Alexander Tsai
Lerner, Josh, Hilary Shane, and Alexander Tsai. "Do Equity Financing Cycles Matter?: Evidence from Biotechnology Alliances." Journal of Financial Economics 67, no. 3 (March 2003): 411–446. (Earlier versions distributed as HBS Working Paper No. 00-038 and NBER Working Paper No. 7464.)
- Web
Biotechnology | Baker Library | Bloomberg Center | Harvard Business School
Guides Biotechnology Biotechnology This guide points to the best biotech focused resources available to the HBS community. See also the related research guide on Medical Devices, Pharmaceuticals, and Health...
View Details
- February 2012
- Article
A 'Core Periphery' Framework to Navigate Emerging Market Governments—Qualitative Evidence from a Biotechnology Multinational
By: Prithwiraj Choudhury, James Geraghty and Tarun Khanna
We build on the emerging literature of influence-based models to study how multinational firms can navigate host governments. Our "core-periphery" framework posits that the actions that an MNC takes with actors in what we call the "periphery"—comprised of state,...
View Details
Keywords:
Emerging Markets;
Multinational Firms and Management;
Business and Government Relations;
Power and Influence;
Framework;
Biotechnology Industry;
Massachusetts;
Brazil;
China;
Costa Rica;
France;
India
Choudhury, Prithwiraj, James Geraghty, and Tarun Khanna. "A 'Core Periphery' Framework to Navigate Emerging Market Governments—Qualitative Evidence from a Biotechnology Multinational." Global Strategy Journal 2, no. 1 (February 2012): 71–87.
- Article
Using Equity Participation to Support Exchange: Evidence from the Biotechnology Industry
By: Gary P. Pisano
Pisano, Gary P. "Using Equity Participation to Support Exchange: Evidence from the Biotechnology Industry." Journal of Law, Economics & Organization 5, no. 1 (Spring 1989): 109–126.
- Article
The Control of Technology Alliances: An Empirical Analysis of the Biotechnology Industry
By: Josh Lerner and Robert P. Merges
Lerner, Josh, and Robert P. Merges. "The Control of Technology Alliances: An Empirical Analysis of the Biotechnology Industry." Journal of Industrial Economics 46, no. 2 (June 1998): 125–156. (Special Symposium "Inside the Pin Factory": Empirical Studies Augmented by Manager Interviews.)
- 12 PM – 1 PM EDT, 26 May 2021
- Virtual Programming
Perspectives in Health: On Biotechnology Capital Strategy and the Future of Therapeutics
HBS Professor Amitabh Chandra will lead a discussion with Katrine Bosley to discuss the explosion of new ideas, capital in Life Sciences and the implications this has on the next generation of therapeutics. This hour-long discussion will include a Q&A for participants...
View Details
- Article
The Governance of Innovation: Vertical Integration and Collaborative Arrangements in the Biotechnology Industry
By: Gary P. Pisano
Pisano, Gary P. "The Governance of Innovation: Vertical Integration and Collaborative Arrangements in the Biotechnology Industry." Research Policy 20, no. 3 (June 1991): 237–249.
- September 2020
- Case
Minerva 2010: Turbulent Times
By: John R. Wells and Benjamin Weinstock
In 2010, amid a flurry of new discoveries, Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), raised $6.6 million to test her new cancer drugs in mice. It had been more than 6 years since she had announced that she and her small team at...
View Details
Wells, John R., and Benjamin Weinstock. "Minerva 2010: Turbulent Times." Harvard Business School Case 721-390, September 2020.
- 1989
- Chapter
Collaborative Product Development and the Market for Know-How: Strategies and Structures in the Biotechnology Industry
By: Gary P. Pisano and Paul Mang
Keywords:
Product Development;
Innovation Strategy;
Knowledge Management;
Industry Structures;
Biotechnology Industry
Pisano, Gary P., and Paul Mang. "Collaborative Product Development and the Market for Know-How: Strategies and Structures in the Biotechnology Industry." In Research on Technological Innovation, Management, and Policy. Vol. 4, edited by Richard S. Rosenbloom and Robert A. Burgelman. Greenwich, CT: JAI Press, 1989.
- October 2016 (Revised February 2017)
- Teaching Note
Alvogen
By: Daniel Isenberg, William R. Kerr and Alexis Brownell
Alvogen is an Icelandic pharmaceutical company that makes and sells generic drugs. Founder and CEO Robert Wessman is deciding whether to take on private equity investors willing to buy out all shareholders, merge with a large and publicly-traded US pharmaceutical...
View Details